Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026

GLAND PHARMA LIMITED GLAND November 09, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Bandra Mumbai - 400 001 (East), Mumbai - 400 051 Scrip Code: 543245 Symbol: GLAND (ISIN: INE068V01023) Dear Sir/Madam, Sub: Appointment of Chief Investment Officer for Gland Pharma International Pte. Ltd (Wholly- owned subsidiary of Gland Pharma Limited) We would like to inform you that Mr. Xiao Le has been appointed as the Chief Investment Officer of Gland Pharma International Pte. Ltd., (‘Gland Singapore’) the Wholly-owned subsidiary of the Company, effective November 09, 2026. Mr. Xiao Le will be responsible for exploring various investment opportunities and to improve M&A capability for Gland in the United States of America, China, Singapore and other countries. Mr. Xiao Le shall be reporting to the CEO of Gland Singapore. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in Annexure-A enclosed herewith. This is for your information and records. Yours truly, For Gland Pharma Limited Sampath Kumar Pallerlamudi Company Secretary and Compliance Officer Encl: Annexure A Regd. Office: Corporate Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads Plot No. 11 & 84, TSIIC Phase: IV D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Pashamylaram (V), Patancheru (M), Sangareddy District Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Hyderabad 502307, Telangana, India Tel: +91-40-30510999 Fax: +91 0-30510800 Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND Continuation Sheet Annexure A Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD/I/3762/2026 dated January 30, 2026 Details of Mr. Xiao Le SI. No Particulars Remarks 1 Reason for change & Mr. Xiao Le, has been appointed as the Chief Investment Officer Date of Change of Gland Singapore, effective November 09, 2026. 2 Brief profile Mr. Xiao Le has over 15 years of experience in investment and assets management in the sphere of medical devices, biopharma, Dx / Tools, healthcare services. He has a rich experience performing all kinds of roles including Chief Financial Officer for MegaRobo Technologies, Singapore; Director on the Board of Directors of CANbridge Pharmaceuticals, United States representing WuXi, Senior Director of M&A and Strategic investments for Wuxi AppTec, Director of Dimensions Capital, and various roles in Middleton Gardiner Group, LLC; NYSE, Bank of America Merrill Lynch, etc. He has worked in various countries like Singapore, China and the Unites States of America. Mr. Xiao Le holds a Bachelor’s degree in Bio-engineering from The Johns Hopkins University and a Master’s degree in Finance from The Massachusetts Institute of Technology. 3 Disclosure of relationships Not Applicable between director 4 Information as required Not Applicable pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018